Global Tumor Immune Cell Therapy Market Outlook, In‑Depth Analysis & Forecast to 2031

1 Study Coverage
1.1 Introduction to Tumor Immune Cell Therapy: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Tumor Immune Cell Therapy Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Immune Checkpoint Inhibitors
1.2.3 Chimeric Antigen Receptor T-cell Therapy
1.2.4 Tumor-Infiltrating Lymphocytes Therapy
1.2.5 Cancer Vaccines
1.2.6 Bispecific Antibodies
1.2.7 Cytokine Therapy
1.3 Market Segmentation by Application
1.3.1 Global Tumor Immune Cell Therapy Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hematological Tumors
1.3.3 Solid Tumors
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Tumor Immune Cell Therapy Revenue Estimates and Forecasts 2020-2031
2.2 Global Tumor Immune Cell Therapy Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Tumor Immune Cell Therapy Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Tumor Immune Cell Therapy Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 Immune Checkpoint Inhibitors Market Size by Players
3.3.2 Chimeric Antigen Receptor T-cell Therapy Market Size by Players
3.3.3 Tumor-Infiltrating Lymphocytes Therapy Market Size by Players
3.3.4 Cancer Vaccines Market Size by Players
3.3.5 Bispecific Antibodies Market Size by Players
3.3.6 Cytokine Therapy Market Size by Players
3.4 Global Tumor Immune Cell Therapy Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Tumor Immune Cell Therapy Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Tumor Immune Cell Therapy Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Tumor Immune Cell Therapy Market Size by Type (2020-2031)
6.4 North America Tumor Immune Cell Therapy Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Tumor Immune Cell Therapy Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Tumor Immune Cell Therapy Market Size by Type (2020-2031)
7.4 Europe Tumor Immune Cell Therapy Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Tumor Immune Cell Therapy Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Tumor Immune Cell Therapy Market Size by Type (2020-2031)
8.4 Asia-Pacific Tumor Immune Cell Therapy Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Tumor Immune Cell Therapy Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Tumor Immune Cell Therapy Market Size by Type (2020-2031)
9.4 Central and South America Tumor Immune Cell Therapy Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Tumor Immune Cell Therapy Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Tumor Immune Cell Therapy Market Size by Type (2020-2031)
10.4 Middle East and Africa Tumor Immune Cell Therapy Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Tumor Immune Cell Therapy Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 MEDINET Co
11.1.1 MEDINET Co Corporation Information
11.1.2 MEDINET Co Business Overview
11.1.3 MEDINET Co Tumor Immune Cell Therapy Product Features and Attributes
11.1.4 MEDINET Co Tumor Immune Cell Therapy Revenue and Gross Margin (2020-2025)
11.1.5 MEDINET Co Tumor Immune Cell Therapy Revenue by Product in 2024
11.1.6 MEDINET Co Tumor Immune Cell Therapy Revenue by Application in 2024
11.1.7 MEDINET Co Tumor Immune Cell Therapy Revenue by Geographic Area in 2024
11.1.8 MEDINET Co Tumor Immune Cell Therapy SWOT Analysis
11.1.9 MEDINET Co Recent Developments
11.2 Erytech
11.2.1 Erytech Corporation Information
11.2.2 Erytech Business Overview
11.2.3 Erytech Tumor Immune Cell Therapy Product Features and Attributes
11.2.4 Erytech Tumor Immune Cell Therapy Revenue and Gross Margin (2020-2025)
11.2.5 Erytech Tumor Immune Cell Therapy Revenue by Product in 2024
11.2.6 Erytech Tumor Immune Cell Therapy Revenue by Application in 2024
11.2.7 Erytech Tumor Immune Cell Therapy Revenue by Geographic Area in 2024
11.2.8 Erytech Tumor Immune Cell Therapy SWOT Analysis
11.2.9 Erytech Recent Developments
11.3 Seta Clinic Group
11.3.1 Seta Clinic Group Corporation Information
11.3.2 Seta Clinic Group Business Overview
11.3.3 Seta Clinic Group Tumor Immune Cell Therapy Product Features and Attributes
11.3.4 Seta Clinic Group Tumor Immune Cell Therapy Revenue and Gross Margin (2020-2025)
11.3.5 Seta Clinic Group Tumor Immune Cell Therapy Revenue by Product in 2024
11.3.6 Seta Clinic Group Tumor Immune Cell Therapy Revenue by Application in 2024
11.3.7 Seta Clinic Group Tumor Immune Cell Therapy Revenue by Geographic Area in 2024
11.3.8 Seta Clinic Group Tumor Immune Cell Therapy SWOT Analysis
11.3.9 Seta Clinic Group Recent Developments
11.4 Takeda
11.4.1 Takeda Corporation Information
11.4.2 Takeda Business Overview
11.4.3 Takeda Tumor Immune Cell Therapy Product Features and Attributes
11.4.4 Takeda Tumor Immune Cell Therapy Revenue and Gross Margin (2020-2025)
11.4.5 Takeda Tumor Immune Cell Therapy Revenue by Product in 2024
11.4.6 Takeda Tumor Immune Cell Therapy Revenue by Application in 2024
11.4.7 Takeda Tumor Immune Cell Therapy Revenue by Geographic Area in 2024
11.4.8 Takeda Tumor Immune Cell Therapy SWOT Analysis
11.4.9 Takeda Recent Developments
11.5 SBI Holdings
11.5.1 SBI Holdings Corporation Information
11.5.2 SBI Holdings Business Overview
11.5.3 SBI Holdings Tumor Immune Cell Therapy Product Features and Attributes
11.5.4 SBI Holdings Tumor Immune Cell Therapy Revenue and Gross Margin (2020-2025)
11.5.5 SBI Holdings Tumor Immune Cell Therapy Revenue by Product in 2024
11.5.6 SBI Holdings Tumor Immune Cell Therapy Revenue by Application in 2024
11.5.7 SBI Holdings Tumor Immune Cell Therapy Revenue by Geographic Area in 2024
11.5.8 SBI Holdings Tumor Immune Cell Therapy SWOT Analysis
11.5.9 SBI Holdings Recent Developments
11.6 Oxford BioTherapeutics
11.6.1 Oxford BioTherapeutics Corporation Information
11.6.2 Oxford BioTherapeutics Business Overview
11.6.3 Oxford BioTherapeutics Tumor Immune Cell Therapy Product Features and Attributes
11.6.4 Oxford BioTherapeutics Tumor Immune Cell Therapy Revenue and Gross Margin (2020-2025)
11.6.5 Oxford BioTherapeutics Recent Developments
11.7 Fate Therapeutics
11.7.1 Fate Therapeutics Corporation Information
11.7.2 Fate Therapeutics Business Overview
11.7.3 Fate Therapeutics Tumor Immune Cell Therapy Product Features and Attributes
11.7.4 Fate Therapeutics Tumor Immune Cell Therapy Revenue and Gross Margin (2020-2025)
11.7.5 Fate Therapeutics Recent Developments
11.8 Gilead Sciences
11.8.1 Gilead Sciences Corporation Information
11.8.2 Gilead Sciences Business Overview
11.8.3 Gilead Sciences Tumor Immune Cell Therapy Product Features and Attributes
11.8.4 Gilead Sciences Tumor Immune Cell Therapy Revenue and Gross Margin (2020-2025)
11.8.5 Gilead Sciences Recent Developments
11.9 Novartis
11.9.1 Novartis Corporation Information
11.9.2 Novartis Business Overview
11.9.3 Novartis Tumor Immune Cell Therapy Product Features and Attributes
11.9.4 Novartis Tumor Immune Cell Therapy Revenue and Gross Margin (2020-2025)
11.9.5 Novartis Recent Developments
11.10 Osiris
11.10.1 Osiris Corporation Information
11.10.2 Osiris Business Overview
11.10.3 Osiris Tumor Immune Cell Therapy Product Features and Attributes
11.10.4 Osiris Tumor Immune Cell Therapy Revenue and Gross Margin (2020-2025)
11.10.5 Company Ten Recent Developments
11.11 Vericel Corporation
11.11.1 Vericel Corporation Corporation Information
11.11.2 Vericel Corporation Business Overview
11.11.3 Vericel Corporation Tumor Immune Cell Therapy Product Features and Attributes
11.11.4 Vericel Corporation Tumor Immune Cell Therapy Revenue and Gross Margin (2020-2025)
11.11.5 Vericel Corporation Recent Developments
11.12 Fujifilm Cellular Dynamics
11.12.1 Fujifilm Cellular Dynamics Corporation Information
11.12.2 Fujifilm Cellular Dynamics Business Overview
11.12.3 Fujifilm Cellular Dynamics Tumor Immune Cell Therapy Product Features and Attributes
11.12.4 Fujifilm Cellular Dynamics Tumor Immune Cell Therapy Revenue and Gross Margin (2020-2025)
11.12.5 Fujifilm Cellular Dynamics Recent Developments
11.13 JCR Pharmaceuticals
11.13.1 JCR Pharmaceuticals Corporation Information
11.13.2 JCR Pharmaceuticals Business Overview
11.13.3 JCR Pharmaceuticals Tumor Immune Cell Therapy Product Features and Attributes
11.13.4 JCR Pharmaceuticals Tumor Immune Cell Therapy Revenue and Gross Margin (2020-2025)
11.13.5 JCR Pharmaceuticals Recent Developments
11.14 Beike Biotechnology
11.14.1 Beike Biotechnology Corporation Information
11.14.2 Beike Biotechnology Business Overview
11.14.3 Beike Biotechnology Tumor Immune Cell Therapy Product Features and Attributes
11.14.4 Beike Biotechnology Tumor Immune Cell Therapy Revenue and Gross Margin (2020-2025)
11.14.5 Beike Biotechnology Recent Developments
11.15 Golden Meditech
11.15.1 Golden Meditech Corporation Information
11.15.2 Golden Meditech Business Overview
11.15.3 Golden Meditech Tumor Immune Cell Therapy Product Features and Attributes
11.15.4 Golden Meditech Tumor Immune Cell Therapy Revenue and Gross Margin (2020-2025)
11.15.5 Golden Meditech Recent Developments
11.16 Guanhao Biotech
11.16.1 Guanhao Biotech Corporation Information
11.16.2 Guanhao Biotech Business Overview
11.16.3 Guanhao Biotech Tumor Immune Cell Therapy Product Features and Attributes
11.16.4 Guanhao Biotech Tumor Immune Cell Therapy Revenue and Gross Margin (2020-2025)
11.16.5 Guanhao Biotech Recent Developments
11.17 Beroni Group
11.17.1 Beroni Group Corporation Information
11.17.2 Beroni Group Business Overview
11.17.3 Beroni Group Tumor Immune Cell Therapy Product Features and Attributes
11.17.4 Beroni Group Tumor Immune Cell Therapy Revenue and Gross Margin (2020-2025)
11.17.5 Beroni Group Recent Developments
11.18 Legend Biotech
11.18.1 Legend Biotech Corporation Information
11.18.2 Legend Biotech Business Overview
11.18.3 Legend Biotech Tumor Immune Cell Therapy Product Features and Attributes
11.18.4 Legend Biotech Tumor Immune Cell Therapy Revenue and Gross Margin (2020-2025)
11.18.5 Legend Biotech Recent Developments
12 Tumor Immune Cell TherapyIndustry Chain Analysis
12.1 Tumor Immune Cell Therapy Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Tumor Immune Cell Therapy Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Tumor Immune Cell Therapy Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details

List of Tables
Table 1. Global Tumor Immune Cell Therapy Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Tumor Immune Cell Therapy Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Tumor Immune Cell Therapy Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Tumor Immune Cell Therapy Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Tumor Immune Cell Therapy Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global Tumor Immune Cell Therapy Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global Tumor Immune Cell Therapy Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global Tumor Immune Cell Therapy by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Tumor Immune Cell Therapy as of 2024)
Table 11. Global Tumor Immune Cell Therapy Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global Tumor Immune Cell Therapy Companies Headquarters
Table 13. Global Tumor Immune Cell Therapy Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global Tumor Immune Cell Therapy Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global Tumor Immune Cell Therapy Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global Tumor Immune Cell Therapy Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global Tumor Immune Cell Therapy Revenue by Application (2026-2031) & (US$ Million)
Table 21. Tumor Immune Cell Therapy High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America Tumor Immune Cell Therapy Growth Accelerators and Market Barriers
Table 25. North America Tumor Immune Cell Therapy Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe Tumor Immune Cell Therapy Growth Accelerators and Market Barriers
Table 27. Europe Tumor Immune Cell Therapy Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific Tumor Immune Cell Therapy Growth Accelerators and Market Barriers
Table 29. Asia-Pacific Tumor Immune Cell Therapy Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America Tumor Immune Cell Therapy Investment Opportunities and Key Challenges
Table 31. Central and South America Tumor Immune Cell Therapy Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa Tumor Immune Cell Therapy Investment Opportunities and Key Challenges
Table 33. Middle East and Africa Tumor Immune Cell Therapy Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. MEDINET Co Corporation Information
Table 35. MEDINET Co Description and Major Businesses
Table 36. MEDINET Co Product Features and Attributes
Table 37. MEDINET Co Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. MEDINET Co Revenue Proportion by Product in 2024
Table 39. MEDINET Co Revenue Proportion by Application in 2024
Table 40. MEDINET Co Revenue Proportion by Geographic Area in 2024
Table 41. MEDINET Co Tumor Immune Cell Therapy SWOT Analysis
Table 42. MEDINET Co Recent Developments
Table 43. Erytech Corporation Information
Table 44. Erytech Description and Major Businesses
Table 45. Erytech Product Features and Attributes
Table 46. Erytech Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Erytech Revenue Proportion by Product in 2024
Table 48. Erytech Revenue Proportion by Application in 2024
Table 49. Erytech Revenue Proportion by Geographic Area in 2024
Table 50. Erytech Tumor Immune Cell Therapy SWOT Analysis
Table 51. Erytech Recent Developments
Table 52. Seta Clinic Group Corporation Information
Table 53. Seta Clinic Group Description and Major Businesses
Table 54. Seta Clinic Group Product Features and Attributes
Table 55. Seta Clinic Group Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. Seta Clinic Group Revenue Proportion by Product in 2024
Table 57. Seta Clinic Group Revenue Proportion by Application in 2024
Table 58. Seta Clinic Group Revenue Proportion by Geographic Area in 2024
Table 59. Seta Clinic Group Tumor Immune Cell Therapy SWOT Analysis
Table 60. Seta Clinic Group Recent Developments
Table 61. Takeda Corporation Information
Table 62. Takeda Description and Major Businesses
Table 63. Takeda Product Features and Attributes
Table 64. Takeda Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. Takeda Revenue Proportion by Product in 2024
Table 66. Takeda Revenue Proportion by Application in 2024
Table 67. Takeda Revenue Proportion by Geographic Area in 2024
Table 68. Takeda Tumor Immune Cell Therapy SWOT Analysis
Table 69. Takeda Recent Developments
Table 70. SBI Holdings Corporation Information
Table 71. SBI Holdings Description and Major Businesses
Table 72. SBI Holdings Product Features and Attributes
Table 73. SBI Holdings Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. SBI Holdings Revenue Proportion by Product in 2024
Table 75. SBI Holdings Revenue Proportion by Application in 2024
Table 76. SBI Holdings Revenue Proportion by Geographic Area in 2024
Table 77. SBI Holdings Tumor Immune Cell Therapy SWOT Analysis
Table 78. SBI Holdings Recent Developments
Table 79. Oxford BioTherapeutics Corporation Information
Table 80. Oxford BioTherapeutics Description and Major Businesses
Table 81. Oxford BioTherapeutics Product Features and Attributes
Table 82. Oxford BioTherapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. Oxford BioTherapeutics Recent Developments
Table 84. Fate Therapeutics Corporation Information
Table 85. Fate Therapeutics Description and Major Businesses
Table 86. Fate Therapeutics Product Features and Attributes
Table 87. Fate Therapeutics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. Fate Therapeutics Recent Developments
Table 89. Gilead Sciences Corporation Information
Table 90. Gilead Sciences Description and Major Businesses
Table 91. Gilead Sciences Product Features and Attributes
Table 92. Gilead Sciences Revenue (US$ Million) and Gross Margin (2020-2025)
Table 93. Gilead Sciences Recent Developments
Table 94. Novartis Corporation Information
Table 95. Novartis Description and Major Businesses
Table 96. Novartis Product Features and Attributes
Table 97. Novartis Revenue (US$ Million) and Gross Margin (2020-2025)
Table 98. Novartis Recent Developments
Table 99. Osiris Corporation Information
Table 100. Osiris Description and Major Businesses
Table 101. Osiris Product Features and Attributes
Table 102. Osiris Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. Osiris Recent Developments
Table 104. Vericel Corporation Corporation Information
Table 105. Vericel Corporation Description and Major Businesses
Table 106. Vericel Corporation Product Features and Attributes
Table 107. Vericel Corporation Revenue (US$ Million) and Gross Margin (2020-2025)
Table 108. Vericel Corporation Recent Developments
Table 109. Fujifilm Cellular Dynamics Corporation Information
Table 110. Fujifilm Cellular Dynamics Description and Major Businesses
Table 111. Fujifilm Cellular Dynamics Product Features and Attributes
Table 112. Fujifilm Cellular Dynamics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 113. Fujifilm Cellular Dynamics Recent Developments
Table 114. JCR Pharmaceuticals Corporation Information
Table 115. JCR Pharmaceuticals Description and Major Businesses
Table 116. JCR Pharmaceuticals Product Features and Attributes
Table 117. JCR Pharmaceuticals Revenue (US$ Million) and Gross Margin (2020-2025)
Table 118. JCR Pharmaceuticals Recent Developments
Table 119. Beike Biotechnology Corporation Information
Table 120. Beike Biotechnology Description and Major Businesses
Table 121. Beike Biotechnology Product Features and Attributes
Table 122. Beike Biotechnology Revenue (US$ Million) and Gross Margin (2020-2025)
Table 123. Beike Biotechnology Recent Developments
Table 124. Golden Meditech Corporation Information
Table 125. Golden Meditech Description and Major Businesses
Table 126. Golden Meditech Product Features and Attributes
Table 127. Golden Meditech Revenue (US$ Million) and Gross Margin (2020-2025)
Table 128. Golden Meditech Recent Developments
Table 129. Guanhao Biotech Corporation Information
Table 130. Guanhao Biotech Description and Major Businesses
Table 131. Guanhao Biotech Product Features and Attributes
Table 132. Guanhao Biotech Revenue (US$ Million) and Gross Margin (2020-2025)
Table 133. Guanhao Biotech Recent Developments
Table 134. Beroni Group Corporation Information
Table 135. Beroni Group Description and Major Businesses
Table 136. Beroni Group Product Features and Attributes
Table 137. Beroni Group Revenue (US$ Million) and Gross Margin (2020-2025)
Table 138. Beroni Group Recent Developments
Table 139. Legend Biotech Corporation Information
Table 140. Legend Biotech Description and Major Businesses
Table 141. Legend Biotech Product Features and Attributes
Table 142. Legend Biotech Revenue (US$ Million) and Gross Margin (2020-2025)
Table 143. Legend Biotech Recent Developments
Table 144. Raw Materials Key Suppliers
Table 145. Distributors List
Table 146. Market Trends and Market Evolution
Table 147. Market Drivers and Opportunities
Table 148. Market Challenges, Risks, and Restraints
Table 149. Research Programs/Design for This Report
Table 150. Key Data Information from Secondary Sources
Table 151. Key Data Information from Primary Sources


List of Figures
Figure 1. Tumor Immune Cell Therapy Product Picture
Figure 2. Global Tumor Immune Cell Therapy Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Immune Checkpoint Inhibitors Product Picture
Figure 4. Chimeric Antigen Receptor T-cell Therapy Product Picture
Figure 5. Tumor-Infiltrating Lymphocytes Therapy Product Picture
Figure 6. Cancer Vaccines Product Picture
Figure 7. Bispecific Antibodies Product Picture
Figure 8. Cytokine Therapy Product Picture
Figure 9. Global Tumor Immune Cell Therapy Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 10. Hematological Tumors
Figure 11. Solid Tumors
Figure 12. Tumor Immune Cell Therapy Report Years Considered
Figure 13. Global Tumor Immune Cell Therapy Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global Tumor Immune Cell Therapy Revenue (2020-2031) & (US$ Million)
Figure 15. Global Tumor Immune Cell Therapy Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 16. Global Tumor Immune Cell Therapy Revenue Market Share by Region (2020-2031)
Figure 17. Global Tumor Immune Cell Therapy Revenue Market Share Ranking (2024)
Figure 18. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 19. Immune Checkpoint Inhibitors Revenue Market Share by Player in 2024
Figure 20. Chimeric Antigen Receptor T-cell Therapy Revenue Market Share by Player in 2024
Figure 21. Tumor-Infiltrating Lymphocytes Therapy Revenue Market Share by Player in 2024
Figure 22. Cancer Vaccines Revenue Market Share by Player in 2024
Figure 23. Bispecific Antibodies Revenue Market Share by Player in 2024
Figure 24. Cytokine Therapy Revenue Market Share by Player in 2024
Figure 25. Global Tumor Immune Cell Therapy Revenue Market Share by Type (2020-2031)
Figure 26. Global Tumor Immune Cell Therapy Revenue Market Share by Application (2020-2031)
Figure 27. North America Tumor Immune Cell Therapy Revenue YoY (2020-2031) & (US$ Million)
Figure 28. North America Top 5 Players Tumor Immune Cell Therapy Revenue (US$ Million) in 2024
Figure 29. North America Tumor Immune Cell Therapy Revenue (US$ Million) by Type (2020 - 2031)
Figure 30. North America Tumor Immune Cell Therapy Revenue (US$ Million) by Application (2020-2031)
Figure 31. US Tumor Immune Cell Therapy Revenue (2020-2031) & (US$ Million)
Figure 32. Canada Tumor Immune Cell Therapy Revenue (2020-2031) & (US$ Million)
Figure 33. Mexico Tumor Immune Cell Therapy Revenue (2020-2031) & (US$ Million)
Figure 34. Europe Tumor Immune Cell Therapy Revenue YoY (2020-2031) & (US$ Million)
Figure 35. Europe Top 5 Players Tumor Immune Cell Therapy Revenue (US$ Million) in 2024
Figure 36. Europe Tumor Immune Cell Therapy Revenue (US$ Million) by Type (2020-2031)
Figure 37. Europe Tumor Immune Cell Therapy Revenue (US$ Million) by Application (2020-2031)
Figure 38. Germany Tumor Immune Cell Therapy Revenue (2020-2031) & (US$ Million)
Figure 39. France Tumor Immune Cell Therapy Revenue (2020-2031) & (US$ Million)
Figure 40. U.K. Tumor Immune Cell Therapy Revenue (2020-2031) & (US$ Million)
Figure 41. Italy Tumor Immune Cell Therapy Revenue (2020-2031) & (US$ Million)
Figure 42. Russia Tumor Immune Cell Therapy Revenue (2020-2031) & (US$ Million)
Figure 43. Asia-Pacific Tumor Immune Cell Therapy Revenue YoY (2020-2031) & (US$ Million)
Figure 44. Asia-Pacific Top 8 Players Tumor Immune Cell Therapy Revenue (US$ Million) in 2024
Figure 45. Asia-Pacific Tumor Immune Cell Therapy Revenue (US$ Million) by Type (2020-2031)
Figure 46. Asia-Pacific Tumor Immune Cell Therapy Revenue (US$ Million) by Application (2020-2031)
Figure 47. Indonesia Tumor Immune Cell Therapy Revenue (2020-2031) & (US$ Million)
Figure 48. Japan Tumor Immune Cell Therapy Revenue (2020-2031) & (US$ Million)
Figure 49. South Korea Tumor Immune Cell Therapy Revenue (2020-2031) & (US$ Million)
Figure 50. Australia Tumor Immune Cell Therapy Revenue (2020-2031) & (US$ Million)
Figure 51. India Tumor Immune Cell Therapy Revenue (2020-2031) & (US$ Million)
Figure 52. Indonesia Tumor Immune Cell Therapy Revenue (2020-2031) & (US$ Million)
Figure 53. Vietnam Tumor Immune Cell Therapy Revenue (2020-2031) & (US$ Million)
Figure 54. Malaysia Tumor Immune Cell Therapy Revenue (2020-2031) & (US$ Million)
Figure 55. Philippines Tumor Immune Cell Therapy Revenue (2020-2031) & (US$ Million)
Figure 56. Singapore Tumor Immune Cell Therapy Revenue (2020-2031) & (US$ Million)
Figure 57. Central and South America Tumor Immune Cell Therapy Revenue YoY (2020-2031) & (US$ Million)
Figure 58. Central and South America Top 5 Players Tumor Immune Cell Therapy Revenue (US$ Million) in 2024
Figure 59. Central and South America Tumor Immune Cell Therapy Revenue (US$ Million) by Type (2020-2031)
Figure 60. Central and South America Tumor Immune Cell Therapy Revenue (US$ Million) by Application (2020-2031)
Figure 61. Brazil Tumor Immune Cell Therapy Revenue (2020-2025) & (US$ Million)
Figure 62. Argentina Tumor Immune Cell Therapy Revenue (2020-2025) & (US$ Million)
Figure 63. Middle East and Africa Tumor Immune Cell Therapy Revenue YoY (2020-2031) & (US$ Million)
Figure 64. Middle East and Africa Top 5 Players Tumor Immune Cell Therapy Revenue (US$ Million) in 2024
Figure 65. South America Tumor Immune Cell Therapy Revenue (US$ Million) by Type (2020-2031)
Figure 66. Middle East and Africa Tumor Immune Cell Therapy Revenue (US$ Million) by Application (2020-2031)
Figure 67. GCC Countries Tumor Immune Cell Therapy Revenue (2020-2025) & (US$ Million)
Figure 68. Israel Tumor Immune Cell Therapy Revenue (2020-2025) & (US$ Million)
Figure 69. Egypt Tumor Immune Cell Therapy Revenue (2020-2025) & (US$ Million)
Figure 70. South Africa Tumor Immune Cell Therapy Revenue (2020-2025) & (US$ Million)
Figure 71. Tumor Immune Cell Therapy Industry Chain Mapping
Figure 72. Channels of Distribution (Direct Vs Distribution)
Figure 73. Bottom-up and Top-down Approaches for This Report
Figure 74. Data Triangulation
Figure 75. Key Executives Interviewed

Your Name

Your E-mail

Your message

Submit